
Zanidatamab/Chemotherapy Yields Responses and Is Safe in HER2-Expressing Metastatic Breast Cancer
The addition of zanidatamab (Ziihera) to chemotherapy demonstrated a manageable safety profile and preliminary antitumor activity in heavily pretreated patients with HER2-positive and HER2-low metastatic breast cancer, according to final results from part …